Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Research Progress of m6A RNA Methylation in Skin Diseases. | Biomed Res Int | 2023 | 37124930 | PubTator, text mining | PubMed |
| Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. | Front Genet | 2023 | 37124622 | PubTator, text mining | PubMed |
| Potential genetic therapies based on m6A methylation for skin regeneration: Wound healing and scars/keloids. | Front Bioeng Biotechnol | 2023 | 37122849 | PubTator, text mining | PubMed |
| Characterization of the m6A regulator-mediated methylation modification patterns in oral squamous cell carcinoma. | Sci Rep | 2023 | 37095314 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A)-connected lncRNAs are linked to survival and immune infiltration in glioma patients. | Biosci Rep | 2023 | 37083719 | PubTator, text mining | PubMed |
| Identification of a m6A-related ferroptosis signature as a potential predictive biomarker for lung adenocarcinoma. | BMC Pulm Med | 2023 | 37072786 | PubTator, text mining | PubMed |
| A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma. | Sci Rep | 2023 | 37072493 | PubTator, text mining | PubMed |
| The diverse role of RNA methylation in esophageal cancer. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 37070847 | PubTator, text mining | PubMed |
| Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications. | Biomark Res | 2023 | 37069649 | PubTator, text mining | PubMed |
| The Proteins of mRNA Modification: Writers, Readers, and Erasers. | Annu Rev Biochem | 2023 | 37068770 | PubTator, text mining | PubMed |
| Novel insights into the interplay between m6A modification and programmed cell death in cancer. | Int J Biol Sci | 2023 | 37063421 | PubTator, text mining | PubMed |
| The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma: Identification and validation of targets. | Front Pharmacol | 2023 | 37063301 | PubTator, text mining | PubMed |
| Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma. | Medicine (Baltimore) | 2023 | 37058053 | PubTator, text mining | PubMed |
| Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy. | Biomark Res | 2023 | 37055798 | PubTator, text mining | PubMed |
| Potential Roles of m6A and FTO in Synaptic Connectivity and Major Depressive Disorder. | Int J Mol Sci | 2023 | 37047192 | PubTator, text mining | PubMed |
| N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS). | J Ovarian Res | 2023 | 37046273 | PubTator, text mining | PubMed |
| RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer. | Ann Med | 2023 | 37042849 | PubTator, text mining | PubMed |
| m6A regulator-mediated RNA methylation modification patterns are involved in the regulation of the immune microenvironment in ischaemic cardiomyopathy. | Sci Rep | 2023 | 37041267 | PubTator, text mining | PubMed |
| Gelsolin: A comprehensive pan-cancer analysis of potential prognosis, diagnostic, and immune biomarkers. | Front Genet | 2023 | 37035750 | PubTator, text mining | PubMed |
| The m6A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma. | Front Immunol | 2023 | 37033963 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=16